Keywords
Pharmaceutical Care
Validated tools
Health screening
How to Cite
Abstract
The use of validated questionnaires and tests for detecting health risks has gained prominence in healthcare practice, especially in contexts where accessibility and speed of assessment are essential for clinical decision-making. In this regard, community pharmacies are emerging as an ideal setting for the use of validated questionnaires and tests that enable the early, structured, and reproducible identification of risk situations related to the use of medications.
This review aims to analyze the role of community pharmacists in the application of these questionnaires and tests, while highlighting their role as healthcare providers in secondary prevention and the importance of their collaboration with other healthcare professionals in a proactive, structured, and evidence-based healthcare model.
The key psychometric characteristics of these validated questionnaires and tests, together with their reliability, validity, and feasibility in practice, have been reviewed. Healthcare interventions developed at both the national and international levels are discussed as examples of transferability and replicability to clinical practice in different healthcare contexts.
References
1. Ahmed K, Brown T, Johnson B. Barriers and facilitators to pharmacy-based screening services: a qualitative study. Res Social Adm Pharm. 2021;17(2):345-352.
2. Alberto Armas D. Atención farmacéutica integral para la optimización de los resultados terapéuticos y mejora de uso de benzodiacepinas [tesis doctoral]. La Laguna: Universidad de La Laguna; 2021.
3. Alberto Armas, D.; Hernández García, V.; Román Castillo, Y.; Santana Ayala, J.R.; Capdevila Finestres, F.; Hardisson de la Torre, A.; Rubio Armendáriz, C. Risk Characterization in Patients Using Benzodiazepines While Providing Pharmaceutical Care Dispensing Service. Pharmacy 2024, 12, 120. https://doi.org/10.3390/ pharmacy12040120
4. Alberto Armas, D.; Santana Ayala, J.R.; Román Castillo, Y.; Hardisson de la Torre, A.; Rubio Armendáriz, C. Quality of Life Assessment in Patients Using Benzodiazepines during the COVID-19 Pandemic in a Community Pharmacy Using EuroQol 5D-3L. Pharmacy 2023, 11, 19. https://doi.org/10.3390/ pharmacy11010019
5. American Pharmacists Association (APhA). Pharmacists' authority to initiate therapy: Position Statement. Washington, DC: APhA; 2022.
6. Balaguer Martínez JV. Uso de cuestionarios en ciencias de la salud: nociones básicas de validación y adaptación. Form Act Pediatr Aten Prim. 2023;16:80–85.
7. Brown T, Davis M, Lee C. Physician acceptance of pharmacist-led screening services: a systematic review. BMC Health Serv Res. 2021;21(1):789.
8. Brucki SM, Malheiros SM, Okamoto IH, Bertola L, Nitrini R. Category fluency test: effects of age, gender and education on total scores, clustering and switching in Brazilian Portuguese-speaking subjects. Braz J Med Biol Res. 2004;37(12):1771–1777.
9. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB. Screening for dementia with the memory impairment screen. Neurology. 1999;52(2):231–238.
10. Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Screening and monitoring patients receiving opioid therapy in pain management. Pain Med. 2004;5(1):36–44.
11. Butler SF, Budman SH, Fernandez KC, Jamison RN. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1–2):144–156.
12. Consejo General de Colegios Farmacéuticos. El cribado de cáncer de colon en farmacias: una oportunidad para la salud pública [Internet]. Madrid: Consejo General de Colegios Farmacéuticos; 2023 [citado 11 may 2025]. Disponible en: https://www.farmaceuticos.com/wp-content/uploads/2023/07/Cribado-cancer-colon-farmacias.pdf
13. Consejo General de Colegios Oficiales de Farmacéuticos. Estadísticas de colegiados y farmacias 2022 [Internet]. Madrid: CGCOF; 2023 [citado 11 may 2025]. Disponible en: https://www.farmaceuticos.com/wp-content/uploads/2023/07/Estadisticas-de-Colegiados-y-Farmacias-2022-07072023.pdf
14. Davis M, Ahmed K, Smith A. Enhancing collaboration between pharmacists and physicians in screening programs. J Interprof Care. 2020;34(5):567–574.
15. Doe A, Miller K, Johnson L, Thompson R. Rapid testing for HIV and HCV in US community pharmacies: impact on early detection and linkage to care. Am J Public Health. 2022;112(4):567–574.
16. Federación Internacional Farmacéutica, Organización Mundial de la Salud. Buenas prácticas en farmacia: normas para la mejora del cuidado de la salud [Internet]. Ginebra: OMS/FIP; 2015 [citado 11 may 2025]. Disponible en: https://www.fip.org/files/fip/publications/2015_GPP_Guide_SPA.pdf
17. Federación Internacional Farmacéutica. Report on asthma control services in Asia-Pacific community pharmacies [Internet]. The Hague: FIP; 2023 [citado 11 may 2025]. Disponible en: https://www.fip.org/file/5447
18. Fernández L, Pérez M. Enhancing medication adherence through community pharmacy services: a narrative review. Res Social Adm Pharm. 2023;19(2):234–240.
19. Foro de Atención Farmacéutica-Farmacia Comunitaria (Foro AF-FC), panel de expertos. Guía práctica para los Servicios Profesionales Farmacéuticos Asistenciales desde la Farmacia Comunitaria. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2024.
20. Galindo-Ortego G, González-Pérez R, López-Bravo A, López-Villegas A. Valoración cognitiva en personas mayores: utilidad en atención primaria y farmacia. Rev Esp Geriatr Gerontol. 2019;54(2):90–97.
21. García M, López R, Fernández J. CRIERFAC study: Chronic kidney disease screening in Spanish community pharmacies. Pharm Pract (Granada). 2023;21(1):45-52.
22. González Blanca J, Vicente Romero J. Deshabituación al consumo de tabaco desde las oficinas de farmacia mediante planes multidisciplinares. Rev Esp Salud Publica [Internet]. 2023 [citado 16 feb 2025];97:e202309077. Disponible en: https://www.mscbs.gob.es
23. Hernández García V. Impacto del Seguimiento Farmacoterapéutico (SFT) en usuarios de analgésicos opioides. Identificación de Indicadores de riesgo e Intervención Farmacéutica para la promoción del uso seguro desde la Farmacia Comunitaria [Tesis doctoral]. San Cristóbal de La Laguna: Universidad de La Laguna; 2022.
24. International Pharmaceutical Federation (FIP). Global report on services provided by pharmacists in primary health care [Internet]. The Hague: FIP; 2022 [citado 11 may 2025]. Disponible en: https://www.fip.org/file/5026
25. Johnson L, Lee R. Hypertension screening in UK community pharmacies: outcomes from the NHS BP Check Service. Pharm J. 2020;305(7932):45-50.
26. Knisely JS, Wunsch MJ, Cropsey KL, Campbell ED. Prescription Opioid Misuse Index: a brief questionnaire to assess opioid misuse. J Subst Abuse Treat. 2008;35(4):380–386.
27. Martínez F, García M, López C. Effectiveness of community pharmacy interventions in hypertension management: a systematic review. Cochrane Database Syst Rev. 2019;(6):CD009531.
28. Ministerio de Sanidad. El Ministerio actualiza la cartera de servicios de la farmacia comunitaria. iSanidad. 2023.
29. Ministerio de Sanidad. Las CCAA podrán autorizar test en farmacias como medida de Salud Pública. El Global. 2021.
30. Ministerio de Sanidad. Nota sobre la colaboración de farmacias en cribado de SARS-CoV-2. Madrid: Gobierno de España; 2021.
31. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.
32. Nguyen T, Morley K, Chen T, Lee K, Williams M. Impact of pharmacist interventions on medication adherence in mental health: a systematic review. Int J Clin Pharm. 2021;43(4):765–77.
33. Nguyen T, Wallace L, Chen J, Chaar B, Moles R. Impact of pharmacist interventions on medication adherence in mental health: a systematic review. Res Social Adm Pharm. 2021;17(8):1330–1338.
34. NHS England. NHS Blood Pressure Check Service: interim report. London: NHS England; 2023.
35. O'Reilly CL, Wong E, Chen TF. A feasibility study of community pharmacists performing depression screening services. Res Social Adm Pharm. 2015;11(3):364–71.
36. Organización Mundial de la Salud (OMS), Federación Internacional Farmacéutica (FIP). Buenas prácticas en farmacia: normas para mejorar la atención farmacéutica. Ginebra: OMS; 2022.
37. Organización Panamericana de la Salud (OPS). Servicios farmacéuticos en el primer nivel de atención. Washington, DC: OPS; 2022.
38. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23(10):433–41.
39. Pharmaceutical Society of Australia. Pharmacists in 2023: For patients, for our profession, for Australia’s health system. Canberra: PSA; 2023.
40. Plaza Zamora FJ, Figueira-Gonçalves JM, de Miguel-Díez J. Colaboración del farmacéutico comunitario en el infradiagnóstico de la enfermedad pulmonar obstructiva crónica (EPOC). Open Respir Arch. 2024;6(3):100329.
41. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.
42. Ramada-Rodilla JM, Serra-Pujadas C, Delclós-Clanchet GL. Adaptación cultural y validación de cuestionarios de salud: revisión y recomendaciones metodológicas. Salud Pública Méx. 2013;55(1):57–66.
43. Roca C, Bertomeu V, Benlloch J, Gómez J, Navarro M. Detección e intervención en personas en riesgo de padecer diabetes en farmacias comunitarias. Farmacéuticos Comunitarios [Internet]. 2022 [citado 16 feb 2025];14(1). Disponible en: https://www.farmaceuticoscomunitarios.org/es/journal-article/deteccion-e-intervencion-personas-riesgo-padecer-diabetes-farmacias-comunitarias/full
44. Rodríguez P, Morales M, Ibáñez C, Herrera F. Pharmacist-led adherence interventions in elderly patients: a meta-analysis. BMC Geriatr. 2022;22(1):89.
45. Sarabia Cobo CM, Alconero Camarero AR. Claves para el diseño y validación de cuestionarios en Ciencias de la Salud. Enferm Cardiol. 2019;26(77):69–73.
46. Smith A, Johnson B, Lee C. Patient satisfaction with pharmacy-based screening services: A systematic review. J Pharm Pract. 2022;35(3):123–130.
47. Smith J, Taylor M, Green P, Anderson N. Community pharmacy-based screening for HIV and hepatitis C: a pilot study. J Pharm Pract. 2021;34(2):123–130.
48. Thompson H, Wallace R, Jenkins S, Patel N. Lipid management in community pharmacy settings: a randomized controlled trial. J Clin Lipidol. 2020;14(3):345–352.
49. Tyrer P, Rutherford D, Huggett T. Benzodiazepine dependence: a study of its characteristics in a clinical population. Br J Psychiatry. 1983;143:147–154.
50. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.
51. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442.
52. World Health Organization. Global burden of preventable medication-related harm in health care: a systematic review [Internet]. Geneva: WHO; 2023 [citado 16 feb 2025]. Disponible en: https://iris.who.int/handle/10665/376203
53. Wu SM, Compton PA, Bolus R, Schieffer B, Pham Q, Baria A, Van Vort W, Davis F, Shekelle P, Naliboff BD. The Addiction Behaviors Checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage. 2006;32(4):342–351.
54. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649–655.
55. Iglesias M, Bragado M, Carrasco M, Faus MJ. Evaluación del conocimiento sobre la hipercolesterolemia y adherencia al tratamiento en pacientes atendidos en oficinas de farmacia. Pharmaceutical Care España. 2005;7(1):19–25.
56. O’Reilly CL, Bell JS, Chen TF. Mental health consumers and caregivers as instructors for health professionals: A qualitative study. Social Psychiatry and Psychiatric Epidemiology. 2010;45(5):469–76.
57. Baixauli V, Arnau A, Garcia S, Herraez A. Evaluación de la adherencia al tratamiento mediante test de Morisky-Green y su relación con variables clínicas y socio-demográficas. Rev OFIL-ILAPHAR. 2020;30(4):422–9.
58. James DH, Patel S, Chuang C, Whitty JA. Development and validation of PubPharmQ: A patient-reported questionnaire measuring satisfaction with public health services in pharmacy. Int J Pharm Pract. 2023;31(1):32–40.
59. Huarte-Royo M, Ardanaz E, Larragueta M, Gardeazabal I, Orozco D, Celay J, et al. Evaluación del conocimiento sobre insulina en pacientes con diabetes tipo 2: Validación de un cuestionario en farmacia comunitaria. Pharmaceutical Care España. 2024;26(1):15–23.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2026 Ceres Journal